Drugs / BW-40202
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06917482 Comparator | Jun 2025 → Jul 2026 overdue | — | Shanghai Argo Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Shanghai Argo Biopharmaceutical Co., Ltd. | Argo Biopharma Doses First Patients in Phase II Clinical Trials of siRNA Therapy BW-40202 argobiopharma.com ↗ |
| 2025-09-15 | Shanghai Argo Biopharmaceutical Co., Ltd. | Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH argobiopharma.com ↗ |
| 2025-06-25 | Shanghai Argo Biopharmaceutical Co., Ltd. | Argo Biopharma Announces First Subject Dosed in Phase I Clinical Trial of an Investigational siRNA Therapy BW-40202 Targeting Complement Factor B argobiopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BW-40202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917482 ↗ |
| Route | Subcutaneous | “route of administration is subcutaneous injection” NCT06917482 ↗ |